A supplement derived from whole tomatoes demonstrates the potential to curb accumulated liver fat and mitigate inflammatory responses associated with metabolic dysfunction-associated steatotic liver disease (MASLD). This conclusion was reached by a team of Italian researchers affiliated with the University of Brescia. The findings of their study were published in the Journal of Translational Medicine (JTM).
The specialists focused their latest research on examining how a tomato supplement, enriched with antioxidants, affects liver cells. Their observations revealed a reduction in the levels of lipids accumulating within these cells, specifically including triglycerides and cholesterol esters. Furthermore, they noted a decrease in the concentration of compounds linked to cellular damage and the advancement of inflammation.
In addition, the addition appeared to suppress the activity of proteins integral to the progression of the ailment. These proteins function as signaling molecules implicated in inflammatory cascades, cell death, and fibrosis development—pathways that can ultimately lead to cirrhosis and liver cancer.
The researchers emphasize that this beneficial effect stems not from a single constituent, but from the synergistic action of the array of substances present in tomatoes, notably lycopene and polyphenols. Working together, these compounds target multiple mechanisms driving the disease, proving more potent than when acting in isolation.
Supplements of this nature could potentially complement a nutritious diet; however, their efficacy must be substantiated through formal clinical trials involving human subjects.
About the Author
